KRAS and non-small cell lung carcinoma: Clinical trials have demonstrated the significant efficacy of these inhibitors in non-small-cell lung cancer (NSCLC) harboring the KRAS G12C mutation, with improved progression-free survival and satisfactory safety profiles.